Breaking News
Get 40% Off 0
🤯 Perficient is up a mind-blowing 53%. Our ProPicks AI saw the buying opportunity in March. Read full update
Close

Dr. Reddy’s Laboratories Ltd ADR (RDY)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow Dr. Reddy’s Labs ADR's earnings

Delivery Method

Status

Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
69.24 -2.26    -3.16%
00:35:48 - Real-time Cboe. Currency in USD ( Disclaimer )
  • Volume: 61,149
  • Bid/Ask: 0.00 / 0.00
  • Day's Range: 69.03 - 70.50
Type:  Equity
Market:  United States
Dr. Reddy’s Labs ADR 69.24 -2.26 -3.16%

RDY Financial Summary

 
A brief financial summary of Dr. Reddy’s Laboratories Ltd ADR as well as the most significant critical numbers from each of its financial reports. In addition, some financial ratios derived from these reports are featured. Users can opt to see 4 periods of either annual or quarterly information.

Dr. Reddy's Laboratories Limited reported earnings results for the second quarter ended September 30, 2023. For the second quarter, the company reported sales was INR 68,802 million compared to INR 63,057 million a year ago. Net income was INR 14,800 million compared to INR 11,128 million a year ago. Diluted earnings per share from continuing operations was INR 88.78 compared to INR 66.89 a year ago.

AnnualQuarterly  
Advanced Financial Summary
TTM = Trailing Twelve Months
MRQ = Most Recent Quarter

RDY Income Statement

Gross margin TTM 58.61%
Operating margin TTM 24.9%
Net Profit margin TTM 19.24%
Return on Investment TTM 19.02%
 Total Revenue  Net Income
Period Ending: Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023
Total Revenue 70830 72148 68802 67384
Gross Profit 41483 42203 40368 39553
Operating Income 14786 17848 16501 17099
Net Income 13070 13789 14800 14025

RDY Balance Sheet

Quick Ratio MRQ 0
Current Ratio MRQ 2.58
LT Debt to Equity MRQ 0%
Total Debt to Equity MRQ 0%
 Total Assets  Total Liabilities
Period Ending: Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023
Total Assets 387518 372842 347022 335041
Total Liabilities 106968 104992 93936 89781
Total Equity 280550 267850 253086 245260

RDY Cash Flow Statement

Cash Flow/Share TTM 321.85
Revenue/Share TTM 1,629.34
Operating Cash Flow  12.00%
 Cash  Net Change in Cash
Period Ending: Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023
Period Length: 0 Months 0 Months 0 Months 0 Months
Cash From Operating Activities 11520 4737 17926 11250
Cash From Investing Activities -11350 -16180 -4517 -8236
Cash From Financing Activities -533 5282 -7036 -1476
Net Change in Cash -428 -6000 6307 1449
* In Millions of INR (except for per share items)
InvestingPro
Go to Dashboard InvestingPro

Unlock access to over 1000 metrics with InvestingPro

View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.

 
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

RDY Comments

Write your thoughts about Dr. Reddy’s Laboratories Ltd ADR
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email